ABSTRACT
INTRODUCTION
The high attrition rate of drug development programs represents a significant barrier to fully realising the vision of precision oncology 1 . The failure of preclinical model systems to adequately predict efficacy in humans is leading drug developers to seek additional sources of evidence to inform decisions about which targets to pursue 2, 3 .
Following completion of the Human Genome Project there has been rapid progress in identifying inherited genetic variants influencing cancer risk through genome-wide association studies (GWAS) and large-scale sequencing projects 4 . Genome-wide association studies have now have been performed for most common malignancies and many rare tumor types, and over 900 genetic variants have been robustly demonstrated to influence risk 4 .
The insights from these GWAS potentially offer an additional mechanism for selecting drug targets and indications, both key requirements in drug discovery. Risk single-nucleotide polymorphisms (SNPs) in or near a gene that may associate with the activity or expression of the encoded protein therefore can be used as a tool to infer the effect of pharmacological action on the same protein in a trial. Specifically, by extension, disease-associated SNPs identified by GWAS can be explicitly interpreted as a source of randomized human evidence to aid drug target identification and validation.
Several examples serve to illustrate the application of human genetics to inform drug discovery by utilising knowledge of variation in genes associated with disease risk. These include the targeting of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) by statins for treatment of coronary heart disease 5 and ustekinumab, a monoclonal inhibitor of interleukin-12 (IL-12) and IL-23 used to treat inflammatory bowel disease 6 .
Here we have, using GWAS association data for 37 cancers, examined the potential for human genetics to guide cancer drug development and repurposing of current approved drugs. 
MATERIALS AND METHODS

Compiling GWAS data
Linking risk SNPs to target genes
To the extent that they have been deciphered, most GWAS risk SNPs map to non-coding regions of the genome and influence gene regulation. Since spatial proximity between specific genomic regions and chromatin looping interactions are central for the regulation of gene expression the 3D structure of DNA means that gene proximity to the risk SNP does always necessarily equate to target gene. It is however, the case that regulatory effects and hence target genes are generally confined within topologically associated domains (TADs) of the genome. To link risk SNPs to target genes we therefore adopted three strategies.
For linkage disequilibrium (LD) based annotation, an approach similar to that adopted by Finan et al., 2017 8 . These data makes use of Hi-C data described in Dixon et al., 2015 11 . TAD boundaries were identified using the insulation score approach proposed by Crane et al., 2015 12 at 40kb resolution. confidence intervals. A P-value of 0.05 (two-sided) was considered as statistically significant.
All statistical calculations were performed using R version 3.2 software.
Druggability annotation of target genes
Targets of FDA-approved drugs were obtained from Santos et al., 2017 15 . 
RESULTS
Linking risk SNPs to target genes
Across 37 cancers we identified 955 risk loci. To link sentinel risk SNPs to respective target gene(s), we first considered genes within regions of LD to which risk SNPs mapped, imposing a range of r 2 thresholds. After which, we considered all genes localising within the risk SNPdefined TAD boundaries. Finally, we based linkage on the gene prioritisation approach implemented in DEPICT 13 . These three approaches yielded between 394 and 7,379 proteincoding target genes ( Fig. 1, Supplementary Tables 1-3 ).
Genetic association enrichment for approved drugs
By interrogating the Informa Pharmaprojects database, we identified 1,706 unique genes that were the target of 3,435 unique therapeutic agents for cancer (Supplementary Table   4 ). These were grouped according to the furthest point reached across five stages of drug development pipeline: (1) Pre-clinical (i.e. in vitro and in vivo dosing and toxicity assessment), (2) Phase I (safety and dosage), (3) Phase II (efficacy and side effects), (4) Phase III and pre-registration (efficacy and monitoring of adverse reactions), (5) Approved.
We first considered all targets from the Pre-clinical stage and assessed the level of enrichment for being successfully approved conferred by genetic information. All of the methods linking SNPs to target genes provided evidence for enrichment. For the LD-based assessment enrichment was strongly correlated with r 2 values; imposing a r 2 value >0.9 resulted in 2.00-fold improvement in targeting of Pre-clinical drugs (95% CI: 1.14-3.48, Fig. 2A , Table 1 ). The comparative enrichment associated with COSMIC catalogued CSGs was 6.61-fold (95% CI: 3.17-13.78, P = 2.23 x 10 -6 , Fig. 2A , Table 1 ).
P=0.02,
We reasoned that a target's failure to progress along the Pre-clinical and Phase I stages is often for reasons unrelated to efficacy, and therefore next considered all targets from Phase II and above, and assessed the degree of enrichment for approval conferred by genetic information. As with the analysis of pre-clinical targets incorporating genetic association information led to enrichment for approval (Fig. 2B, Table 2 ). The strongest enrichment from the LD-based approach was attained after imposing an r 2 value >0.9 which was associated with a significant 2.75-fold difference (95% CI: 1.42-5.35, P = 4.2 x 10 -3 , Fig. 2B ).
The comparative enrichment associated with COSMIC catalogued CSGs was 5.72-fold (95% CI: 2.35-13.89, P = 8.41 x 10 -5 ).
Potential for re-purposing non cancer drugs
To explore the application of genetics to inform drug re-purposing we first identified approved drugs used in the treatment of non-oncological disease. We then examined discordant pairing of drug indications and cancer associations. We identified 15 genes for which an approved drug is currently available with genetic support ( 
Availability of cancer germline genetic information
Supporting cancer germline genetic information for prospective targets is available from https://cansar.icr.ac.uk/ (Figure 3) . For each uniprot identifier, a report has been generated detailing whether the given gene has been annotated as containing cancer-causing germline mutations by the COSMIC germline cancer gene census 14 , as well as whether any variants from cancer genome-wide association studies map to the gene (Figure 3 ).
DISCUSSION
Our findings support the potential of human genetics to guide the identification of drug targets, addressing a productivity-limiting step in drug development and a bottleneck to realising the vision of precision oncology. Specifically, we have demonstrated that knowledge of cancer susceptibility genes identified by GWAS can be used to maximise discovery of likely Pre-clinical and Phase II targets, thereby empowering drug development programs. Our analysis benefits from the larger of risk loci for cancer that have been identified over recent years thereby providing greater power than earlier studies 1 .
Significant enrichment of pre-clinical and phase II targets was also shown by incorporating information on the classical CSGs. Given that many of the CSGs are somatically mutated these targets may have already directly influenced recent drug development programs.
Indeed, we observed a highly significant enrichment for CSGs being selected for pre-clinical validation per se (OR=11.37; CI=7.44-17.37; P=5.19 × 10 -20 ), which is greater than that afforded to genes simply implicated by GWAS (r 2 >0.9 targets (OR=1.44; CI=1.14-1.81;
P=0.003).
We employed a number of methods to map target genes to cancer risk SNPs, incorporating LD blocks, TAD regions and gene expression. We found that genes implicated by LD r 2 >0.9 method showed the greatest enrichment for drug approval. While compatible with the functional basis of many GWAS associations being due to the most proximal gene(s), this does not preclude the possibility of longer-range tissue-specific mechanisms that are less amenable to detection by our approach. Therefore future endeavours of this kind will likely benefit from more detailed experimental investigation of the biological mechanism underpinning cancer risk loci. While the TAD-based strategy is likely to be always beset by the issue of capturing too many genes, strategies based on integration of GWAS and multiomics as per DEPICT 13 are likely to improve making them attractive sources of genetic information. To investigate regulatory interactions across all cancer risk loci we made use of publicly available Hi-C data from human embryonic stem-cells, noting the observation of Dixon et al., 2012 25 that TAD boundaries are relatively stable across cell types. However, the increasing availability of tissue-and cancer-specific Hi-C data is likely to improve efforts to identify target genes of specific cancer risk regions.
In concert with our primary analysis we identified a number of possible opportunities for drug re-purposing, informed by cancer germline genetics. These extend the potential of preexisting therapies and highlight that pathways subverted by cancers may also be altered in other diseases.
For pragmatic purposes we considered all cancers assuming generic effects exist at least across some cancers in order to maximise study power. We do however acknowledge that this is in essence crude since certain cancer subtypes can show specific associations with risk SNPs, reflective of differences in their biology. For example, ER-positive and negative breast cancers 26,27 as well as combinations of 1p/19q co-deletion, TERT promoter and IDH mutation in glioma 28, 29 . The future availability of larger datasets which will afford the identification of additional risk SNPs will open up the possibility of fine-tuned analyses. In addition we make the assumption that cancer risk variants act directly to influence cancer initiation or progression. However, this does not preclude the existence of a limited subset which may have indirect mechanisms, such as at 15q25.1 where the association with lung cancer is likely due to smoking 30 .
One caveat to using all forms of germline genetics as a mechanism for prioritisation of drug development is the assumption that susceptibility per se is also reflective of progression, which may not always be the case. As with other studies, we have used drug approval as a surrogate for drug efficacy. This assumption will only however serve to make our estimates conservative. We additionally acknowledge our lack of inclusion of generic drugs, however as the vast majority of these have a broad range of targets we do not regard this as significantly impacting our findings. Considering the extent to which cancer genes implicated by GWAS that are not currently in the drug development pipeline might represent good candidates we performed multi-faceted druggability analyses incorporating assessments of the 3D structures of the target protein and any associated protein complexes, chemical properties of known ligands of the target, and the target's position and role within the human interactome. Ranking target-indication pairings by criteria including novelty relative to existing targets and predicted attrition risk (Supplementary Tables 5 and   6 ). Of 1,292 genes annotated to GWAS SNPs by r 2 >0.9; 977, 486 and 1,287 had druggability assessments by network, structure and ligand-based prediction respectively. Of note is the observation that 29 of these can be targeted by existing high-quality probes and thus represent good candidates for being prioritised in for future studies.
In conclusion, we have demonstrated enrichment for targets implicated by cancer risk variants being more successful in the drug development pipeline, providing a rationale for germline genetics empowering cancer drug discovery. Mapping approved drug targets back to cancer GWAS signals enables identification of both novel drug targets and patient populations. To benefit the wider community the cancer germline information used in this study is available at https://cansar.icr.ac.uk. Collectively our findings show the value of incorporating information from germline cancer genetics as part of interdisciplinary, datadriven approaches to inform drug discovery in oncology. 
